More on AB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $37.15 |
|
|||
| Open | $37.04 | ||||
| 52 Wk High | $26.24 | ||||
| 52 Wk Low | $16.11 | ||||
| Day High | $37.25 | ||||
| Day Low | $36.91 | ||||
| P/E | 21.88 | ||||
| EPS | $1.70 | ||||
| Volume | 187,332 | ||||
- AllianceBernstein (AB) PT Raised to $38 at TD Cowen
- Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jul 13
- AllianceBernstein AUM rises to $905B at end of June 2026
- AB Announces June 30, 2026 Assets Under Management
- AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs
- AllianceBernstein (AB) PT Lowered to $37 at TD Cowen
- AB to Report Second Quarter 2026 Results on July 28, 2026
- AB Science reports phase 1 data for AB8939 plus venetoclax in AML
- AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
- AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
Entities mentioned with AB
- Earnings | View Related Stories »
- Sanford C. Bernstein | View Related Stories »
- Definitive Agreement | View Related Stories »
- Barclays | View Related Stories »
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Citi | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
